Tools   Select Another Resource Report Type

http://www.quretec.com/

Commercial organization that builds software for collection, management, and analysis of complex data, most typical in biomedical domain. The solutions are generic and can be used for multitude of uses and application domains.

Proper citation: Quretec (RRID:SCR_003826) Copy   

•   Source: SciCrunch Registry

http://www.onyx.com/

November 2020, Onyx merged with Legacy Acquisition Corp. to form PARTS iD, Inc. Our data intelligence, integrated platforms, product cataloging, digital marketing expertise, and virtual warehousing have ensured our continued leadership in the competitive marketplace.

Proper citation: Onyx Pharmaceuticals (RRID:SCR_003782) Copy   

•   Source: SciCrunch Registry

http://www.sciencewise-erc.org.uk/cms/

Sciencewise-ERC is the UK's national center for public dialogue in policy making involving science and technology issues. It provides co-funding and specialist advice and support to Government departments and agencies to develop and commission public dialogue activities in emerging areas of science and technology. It consists of a comprehensive online resource of information, advice and guidance together with a wide range of support services aimed at policy makers and all the different stakeholders involved in science and technology policy making, including the public. Sciencewise-ERC works with central Government and its agencies, and executive, advisory and non-departmental public bodies. Some of the Government departments include the Department for Environment, Food and Rural Affairs (Defra), the Department of Energy and Climate Change (DECC) and most recently HM Treasury.

Proper citation: Sciencewise (RRID:SCR_003780) Copy   

•   Source: SciCrunch Registry

http://www.efpia.eu/

Federation representing the pharmaceutical industry operating in Europe. Through its direct membership of 33 national associations and 40 leading pharmaceutical companies, it is the voice on the EU scene of 1,900 companies committed to researching, developing and manufacturing new medical treatments. In addition, it is active in partnering in EU Research programmes, such as the IMI (Innovative Medicines Initiative), Europe's largest public-private partnerships. They also work on corporate social responsibility initiatives with others healthcare stakeholders, such as patient groups and healthcare professionals. EFPIA has specialized committees and task forces focused on key areas of activity. EFPIA also includes two specialized groups focusing on vaccines and biotechnology, respectively: * Vaccines Europe (formerly European Vaccine Manufacturers, EVM) produces approximately 80% of vaccines used worldwide * European Biopharmaceutical Enterprises (EBE) harness biotechnology to develop approximately one-fifth of new medicines

Proper citation: European Federation of Pharmaceutical Industries and Associations (RRID:SCR_003820) Copy   

•   Source: SciCrunch Registry

http://www.avidrp.com/

Subsidiary of Eli Lilly and Company who develops new molecular imaging agents capable of changing the medical management of significant, chronic human diseases by identifying the first stages of pathological change, potentially assisting in earlier diagnosis, and better management and development of new therapies. The company has developed a radioactive tracer called florbetapir (18F). Florbetapir can be used to detect beta amyloid plaques in patients with memory problems using positron emission tomography (PET) scans, making the company the first to bring to market an FDA-approved method that can directly detect this hallmark pathology of Alzheimer's disease.

Proper citation: Avid Radiopharmaceuticals (RRID:SCR_003786) Copy   

•   Source: SciCrunch Registry

http://www.asthma.org.uk/

Charity that aims to significantly reduce the number of asthma deaths, hospitalizations and living lives compromised by asthma helping over five million people with asthma in the UK through research, campaigning, health promotion and engagement with the asthma community. Asthma UK is a significant investor in asthma research within the UK and to date has invested over 50 million pounds into research for better treatments and ultimately a cure for asthma.

Proper citation: Asthma UK (RRID:SCR_003815) Copy   

•   Source: SciCrunch Registry

http://www.eurordis.org/

EURORDIS is a non-governmental patient-driven alliance of patient organizations and individuals active in the field of rare diseases, dedicated to improving the quality of life of all people living with rare diseases in Europe. It is a not-for-profit organization and represents more than 479 rare disease organizations in 45 different countries (of which 25 are EU Member States), covering more than 4,000 rare diseases. It is therefore the voice of the 30 million patients affected by rare diseases throughout Europe. EURORDIS aims at improving the quality of life of people living with rare diseases in Europe through advocacy at the European level, support for research and drug development, networking patient groups, raising awareness and other actions designed to fight against the impact of rare diseases on the lives of patients and family. EURORDIS' training programs and resources are designed to strengthen the capacity of rare disease patients' representatives. Training empowers patients' representatives to advocate effectively for rare diseases at both the local and EU level. Key issues affecting patients of Rare Diseases on which we actively work: * Sustaining rare diseases as an EU public health priority * Making Rare Diseases A Public Health Priority In All Member States * Rare Diseases: An International Public Health Priority * Improving Access To Orphan Drugs * Improving Access To Quality Care * Promoting cross-border healthcare and patient mobility * Bridging Patients And Research * Genetic testing and newborn screening

Proper citation: EURORDIS (RRID:SCR_003814) Copy   

•   Source: SciCrunch Registry

http://www.alzheimersresearchuk.org/

The UK's leading dementia research charity that funds world-class, pioneering scientists at leading universities to find preventions, treatments and a cure for dementia.

Proper citation: Alzheimer's Research UK (RRID:SCR_003847) Copy   

•   Source: SciCrunch Registry

http://www.big-project.eu/

A consortium working towards the definition and implementation of a clear strategy that tackles the necessary efforts of Big Data (in terms of research and innovation) while also providing supporting actions for the successful implementation of the Big Data economy. Building an industrial community around Big Data in Europe is the priority of this project, together with setting up the necessary collaboration and dissemination infrastructure to link technology suppliers, integrators and leading user organizations.

Proper citation: Big Data Public Private Forum (RRID:SCR_003837) Copy   

•   Source: SciCrunch Registry

https://www.nephropath.com/

Commercial service interpreting renal biopsies using 14 board-certified, fellowship-trained pathologists with decades of experience. They provide doctors with a high quality, clinico-pathologic discussion by the pathologist that read the case. It is their goal to help equip doctors with the results they need to deliver the most effective patient care possible. That is why they deliver same-day biopsy results, including EM, because they know that time often has a critical effect on the outcome of many renal diseases. Nephropath also offers PLA2R serum testing and will soon be offering neuropathology services including muscle and nerve biopsy services.Nephropath is now Arkana Laboratories.

Proper citation: Nephropath (RRID:SCR_003995) Copy   

•   Source: SciCrunch Registry

http://www.biomedicumgenomics.fi/

Organization that provides academic and industrial clients access to functional genomics technologies, services and partnering solutions including genome-wide expression, copy number profiling, miRNA expression, DNA-protein interaction (ChIP-on-chip), Illumina high-throughput sequencing including nucleic acid quality and quantity assessment. For gene silencing and ectopic expression purposes, they offer high-titer shRNA and ORF lentiviruses targeting genes of interest. They also offer customized services e.g. preparation of gain or loss-of-function cell lines and protein interactomics-based services (yeast two-hybrid). In addition, they provide access to wide array of computational data analyses. BMGen also offers partnering deals for clients interested in customized integration of several technologies.

Proper citation: Biomedicum Genomics (RRID:SCR_003907) Copy   

•   Source: SciCrunch Registry

http://www.microsens.co.uk/

Commercial organization specializing in bacterial detection including tuberculosis, therapeutic protein and protein aggregation diseases. * Tools for rapid and simple bacteria and virus extraction including tuberculosis * Seprion technology for the detection and study of protein aggregates and protein aggregation diseases * LiMA technology for the ultra sensitive detection of bacteria and bacterial contamination

Proper citation: Microsens (RRID:SCR_003906) Copy   

•   Source: SciCrunch Registry

http://www.cbioc.com/en/

Commercial organization that discovers, validates & analyzes genomic biomarkers with a focus on body fluid samples. Take advantage of their proven expertise in biomarker signature development and speed up your biomarker studies.

Proper citation: Comprehensive Biomarker Center (RRID:SCR_003901) Copy   

•   Source: SciCrunch Registry

http://www.janssenrnd.com/

Pharmaceutical company with a mission to discover and develop innovative medicines that ease patients'' suffering, and solve the most important unmet medical needs of our time. As one of the Janssen Pharmaceutical Companies, their strategy is to identify the biggest unmet medical needs and match them with the best science, internal or external, to find solutions for patients worldwide. They leverage their world-class discovery and development expertise, and operational excellence, to bring innovative, effective treatments in five therapeutic areas: cardiovascular and metabolism, immunology, infectious diseases and vaccines, neuroscience, and oncology.

Proper citation: Janssen Research and Development (RRID:SCR_003904) Copy   

•   Source: SciCrunch Registry

http://www.flexgen.nl/

A biotechnology company that has developed technology for synthesizing custom microarrays, the FlexArrayer. Its is a desk-top sized instrument which allows the researcher to generate, in their own laboratory, either a custom oligonucleotide array in a single day or oligonucleotide pool in a few days. Recent developments in synthesis chemistry allows many modifications to be incorporated or for alternative chemistries to be considered., THIS RESOURCE IS NO LONGER IN SERVICE. Documented on September 16,2025.

Proper citation: FlexGen (RRID:SCR_003902) Copy   

•   Source: SciCrunch Registry

http://www.hospira.com/

American global pharmaceutical and medical device company with headquarters in Lake Forest, Illinois.Provider of injectable drugs and infusion technologies and global leader in biosimilars. From September 2015 Hospira is part of Pfizer.

Proper citation: Hospira (RRID:SCR_003985) Copy   

•   Source: SciCrunch Registry

http://www.quartzbio.com/

A Swiss service and consulting company specialized in the computational analysis of biomarker data from clinical trials. Their technical expertise spans across multiple biomaker technological platforms such as genetics, transcriptomics, protein assays and cellular assays. Quartz Bio is a spin-off of Merck Serono with the capital of the company entirely owned by its employees.

Proper citation: Quartz Bio (RRID:SCR_003919) Copy   

•   Source: SciCrunch Registry

http://www.althia.es/

A biomedical company in Spain focused on the development of new tools for diagnosis and personalized treatment of oncological diseases and precancerous. It has three areas of activity in permanent innovation: Assistance in Diagnosis / Prognosis in solid and hematological tumors, Translational Research covering the gap between basic and clinical research and advanced radiotherapy treatments based image-guided single dose (SD-IGRT). Their objectives are: * Provide an integrated tissue and tumor molecular phenotype analysis using the most advanced technologies in diagnosis, to guide the most appropriate treatment for each patient. * Discover and validate molecular patterns by molecular systems and platforms including pathology, to generate predictive algorithms through computational biology, evolution and determining the response of patients with a particular tumor profile. Althia has laboratories equipped with the most advanced equipment and technologies in Barcelona and Granada Genyo Center, with offices in Madrid.

Proper citation: Althia (RRID:SCR_003918) Copy   

•   Source: SciCrunch Registry

http://www.cornell.edu/

Private and statutory Ivy League research university in Ithaca, New York. Founded in 1865 by Ezra Cornell and Andrew Dickson White, the university was intended to teach and make contributions in all fields of knowledge—from the classics to the sciences, and from the theoretical to the applied.

Proper citation: Cornell University; New York; USA (RRID:SCR_003998) Copy   

•   Source: SciCrunch Registry

http://www.nxstage.com/

A medical device company that develops, manufactures and markets innovative dialysis systems for the treatment of end-stage renal disease, or ESRD, and acute kidney failure.

Proper citation: NxStage Medical (RRID:SCR_004000) Copy   

•   Source: SciCrunch Registry